potbelli corpor hold pt new ceo alan johnson lay strategi turnaround like take
time maintain hold pt analyst stephen anderson full summari
adami pharmaceut corpor admp buy pt symjepi updat discuss partner
express script hold co esrx buy pt preview threat amazon entri pbm busi earli
 buy pt bring sangamo gene edit platform board wave
solar senior capit ltd sun buy pt well-posit nii asset-bas lend
abl top pick analyst michael diana full summari
corpor event call maxim salesperson inform
inc cover ndr san francisco ceo stephen joyc interim cfo
gregori kalvin execut director ir ken dipte mon feb
cover ndr boston cfo golder wed jun
corp cover kinstling ndr boston cfo ranjan kalia wed
payment data system inc pyd ndr nyc ceo loui hoch cfo tom jewel wed
bring sangamo gene edit platform board
wave oncolog cell therapi
gilead/kit announc collabor
nr use sangamo gene edit platform zinc finger nucleas zfn
develop next-gen cell therapi oncolog includ car-t tcr cell
receptor nkr natur killer cell receptor term deal
gilead make up-front payment elig
receiv mileston across product plu tier royalti
gene edit key technolog gilead car-t space
move beyond initi target like bcma cell matur antigen
target solid liquid tumor gene edit fine-tun
cell therapi modifi gene avoid mis-target side effect
enhanc efficaci disrupt checkpoint sangamo zfn platform
make gene edit high precision/specif multiplex edit
multipl gene singl step still earli stage factor
model first indic yet announc bring
gene edit necessari step gilead expand cell therapi
pipelin view
focu yescarta us launch still earli stage expect
approv europ china japan follow global
presenc late-stag cell cancer gilead posit gener
outyear compani also expand earlier line therapi
addit gilead bcma multipl myeloma target
may fast follow well sever first-gen
tcr alreadi clinic
conclus incorpor gene edit expand pipelin
strengthen gilead posit industri leader cell therapi
approv yescarta first step new oncolog treatment
gene edit first car-t therapi approv bcma next next
wave cell therapi develop target solid tumor blood-born
cancer howev indic come challeng antigen select
avoid mis-target healthi cell penetr solid tumor overcom tumor
microenviron addit bcma multi-billion-dollar opportun
target rel small patient popul indic becom larger expect
allogen cell therapi use shelf vs autolog one patient one
product becom focu car-t compani incorpor gene edit
platform modifi cell overcom challeng eventu go allogen
gilead sangamo zfn platform enabl rapid product zfn candid
target gene sequenc zfn produc induc highli precis genom edit
undetect level target cleavag zfn platform also edit three
gene knockout tcr hla checkpoint insert gene interest
engin tcr nkr
cell therapi long-term play gilead report yescarta revenu
product get start car-t new paradigm take time
work manufactur reimburs us gilead cancer
center certifi prescrib yescarta expect reach popul
geograph gilead posit gener global late
stage b-cell cancer outyear moreov acquir kite gilead first
mover advantag oncolog paradigm shift toward integr cell therapi
treatment regimen begin
click full note
preview threat amazon entri pbm busi
earli stage stock remain under-valued reiter buy
brka nr organ nr announc
partner us employe healthcar ventur believ repres
potenti long-term threat opportun esrx effort still
earli stage
accord drug trend report prescript drug spend inflat
commerci plan y/i y/i lowest rate
esrx ever record
decemb esrx ad share repurchas program
result due tomorrow market close confer call
schedul wednesday et
bottom line would continu buyer esrx ahead result
view stock attract valu opinion esrx bring uniqu valu
proposit largest stand-alone pharmaci benefit manag pbm notabl
abil pass along signific save drug cost custom
believ esrx control drug price inflat commerci plan prescript
drug spend growth lowest rate sinc compani began track
although amzn-brka-jpm partnership could eventu pose threat esrx
time methodolog success ventur remain uncertain specif
ventur still earli plan stage opinion could mani year
ever materi impact pbm market moreov believ
entiti may partner exist pbm manag care compani final view
increas share repurchas plan reflect board confid on-going
strength esrx busi
-brka- healthcar ventur januari brka
announc form partnership improv satisfact reduc
cost within us employe healthcar system partner expect form
independ not-for-profit compani initi focus technolog solut provid
simplifi high-qual transpar healthcar reason cost effort
earli plan stage initi led todd comb invest offic
brka marvel sullivan berchtold manag director beth galetti senior
vice presid
drug trend report februari esrx releas drug trend
report base data collect member esrx-administ plan
prescript drug spend inflat commerci plan y/i
y/i lowest rate esrx ever record driven util
unit cost growth total drug spend fell commerci plan
gener fill rate rose y/i see page detail
look quarter estim revenu flat y/i
compar consensu gross margin y/i compar
consensu adjust ep compar consensu
gaap ep compar consensu also project gener
dispens rate y/i adjust claim volum
y/i expect esrx discuss client win retent rate
compel valuat share current trade ep
adjust ep estim compar peer averag
respect price target deriv use dcf analysi
discount rate termin growth rate impli share trade
adjust ep estim
click full note
new ceo alan johnson lay strategi turnaround
like take time maintain hold pt
maintain hold rate price target follow
releas decemb result
new ceo alan johnson announc five-part strategi reinvigor same-
lower march ep estim manag
cite slower start quarter
also reduc ep estim ep
estim account addit sg spend
support initi well gradual sale improv
believ outcom pbpb on-going strateg review includ
potenti refranchis like limit share price downsid
new ceo alan johnson announc five-part strategi reinvigor same-
restaur sale growth compani post-earn confer call mr
johnson announc follow strategi
seek strateg shop growth plan target new unit growth exist
under-penetrated market expect target east coast rocki
mountain southwest state futur growth
invest market manag expect use menu innov chang
menu board potenti group item price bundl promot
catch customer-fac technolog expect follow-up
invest made technolog focus primarili potbelli perk
loyalti program relat online/mobil capabl
invest franchis system plan fill new executive-level posit
overse compani franchis effort potenti includ effort refranchis
find cost save opportun manag expect use save fund
lower march ep estim manag
cite slower start quarter manag cite difficult y/i sale comparison
strong januari notabl milder weather market higher
inauguration-rel sale washington dc area accordingli lower
comp estim take full year estim
also reduc ep estim
ep estim account addit sg spend
support initi well gradual sale improv
specif estim increment higher sg spend reduc annual
ep though expect reduct mute cost save
howev anticip could take see effect new sales-build
initi ep estim includ annual increment ep upsid
corpor tax reform
believ outcom pbpb strateg review includ potenti
refranchis like limit share price downsid yet model
potenti aggress refranchis particularli yet mention
time sale company-own unit well potenti franchis acquir
like use proce acceler share buy-back program
unchang price target reflect moder comp improv well
modest lift corpor tax reform price target base
combin two methodolog forward price-to-earnings ratio target
revis ep estim yield price target
forward ev/ebitda ratio yield price target combin
methodolog arriv price target round
click full note
symjepi updat discuss partner
manag press releas morn respond concern
regard lack news flow symjepi process still
on-going discuss two potenti partner confid
group capabl produc valu symjepi market
group engag believ later stage dilig may
includ discuss potenti drug buyer wholesal distributor
believ help refin commerci plan
recent model chang recent increas therapeut risk cut
epinephrin pre-fil syring model commerci
assumpt addit push time back pipelin
product model includ inhal
remain hope see deal soon press releas adami
hope see commerci deal symjepi soon
look deal term superior given fact symjepi
approv product recal prior deal watson gener divis
allergan nr propos payment combin
up-front regulatori perform mileston well doubl digit
royalti sale
pipelin heard much compani around pipelin
product hfa inhal steroid hfa albuterol
taper dri powder inhal result recent push
commerci time
compound pharmaci progress hope see steadi progress
assum acquisit us compound work compani
complet process integr quarterli report provid
import look busi
new product platform technolog need simpl user friendli self-
inject devic rise see potenti compani develop
indic focu opioid crisi
mayb new opportun pfs-like product save live yet
factor revenu beyond symjepi
adami announc fda approv epinephrin inject
usp pre-fil single-dos syring emerg
treatment allerg reaction type includ anaphylaxi fda also
approv trade name symjepi
symjepi provid two singl dose syring epinephrin adrenalin
consid drug choic immedi administr acut anaphylact
reaction insect sting bite allerg reaction food nut drug
allergen well idiopath exercise-induc anaphylaxi
second submiss happen junior version
symjepi manag comment product provid patient
addit therapeut choic lower cost small size user-friendli design
click full note
well-posit nii asset-bas
lend abl top pick
net invest incom nii match dividend
abl sourc nii low leverag floating-r
loan sun appear well-posit
maintain ep estim price target
equat in-line best-in-class bdc
sun top pick especi retail investor base
credit risk interest rate risk profil
invest incom nii per share waiver manag fee
small incent fee waiver match dividend ep due
invest gain ep exceed dividend net asset valu
per share
data sun yield invest portfolio versu
due acquisit north mill capit see posit impact
higher libor sun invest portfolio floating-r acquir
loan north mill plu origin exceed elev payoff invest
portfolio grew leverag net cash pend transact also
equiti sun non-accru
recent analyst day januari oper unit sun manag
scp collect specialti financ compani wrapper loan
portfolio credit qualiti growth primari driver scp busi
divers busi differ busi model nich
case non-correl particularli help today hyper-competit environ
cash-flow lend especi sponsor leverag financ loan
impress entir manag team
industri asset-bas lender complement gemino healthcar financ healthcar
asset-bas lender abl sourc sun nii view
favor abl tend less competit better credit qualiti loan
collater current asset mainli account receiv
well-posit abl sourc nii low leverag
million invest capac floating-r loan sun appear
well-posit
maintain ep estim matching/cov dividend
estim includ small amount fee waiver expect
quarterli nii sun reach target leverag know
long take page updat earn model
reiter buy rate price target equat
in-line best-in-class bdc premium bdc warrant
view sun invest portfolio follow uniqu combin
favor attribut high qualiti first-lien floating-r nii
abl non-accru direct exposur energi commod
sector attribut stem strong risk-avers manag
sun top pick especi retail investor next
four quarter expect dividend yield stock price appreci
price target result estim total return
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
